Capricor Therapeutics Soars As FDA Keeps Deramiocel Path Alive

Capricor Therapeutics Inc. stocks have been trading up by 11.28 percent following impactful positive clinical development news.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CAPR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need On CAPR

Shares of Capricor Therapeutics (CAPR) exploded roughly 80–100% after the FDA agreed to review an amended deramiocel filing and Cantor Fitzgerald sharply raised its rating and target.
Cantor boosted CAPR to Overweight from Neutral and hiked its price target to $28 from $3.50, now above the prior analyst mean target of $26.12.
Following a 9–3 negative advisory panel vote on cardiomyopathy, Capricor is refocusing deramiocel’s BLA on upper‑limb function using 24‑month HOPE‑3 data, with the FDA open to reviewing this package and extending the PDUFA date.
Capricor reported Q2 2026 with no revenue, a wider loss, and about $238M in cash, saying current cash and securities should fund operations for at least 12 months.

Live Update At 12:33:26 EDT: On Monday, August 17, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 11.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics (CAPR) is trading like a classic high‑beta biotech story: no revenue, deep losses, big binary catalyst. In Q2 2026, CAPR posted a net loss of about $40.7M and EBITDA around -$40.2M as it gears up for possible deramiocel commercialization. Operating cash burn ran near $31.5M for the quarter, with free cash flow at roughly -$35.5M.

Despite that burn, the balance sheet is a key support for CAPR. The company reported about $237.9M in cash and short‑term investments and roughly $20.9M in pure cash. A current ratio of 7.4 and quick ratio of 7.2 show Capricor is very liquid, with working capital above $200M. Debt is modest relative to equity, with total debt‑to‑equity at 0.37.

More Breaking News

On the chart, CAPR has transformed from a sleepy mid‑single‑digit name to a momentum biotech. The stock closed at $4.21 on 2026/08/13, then ripped to a $6.65 close on 2026/08/14 and pushed to $7.40 on 2026/08/17. Intraday, CAPR shows tight consolidations above $7 and repeated pushes toward $7.40–$7.47. For active traders, this mix of strong cash, heavy losses, and a fresh breakout screams “catalyst‑driven trading vehicle,” not a sleepy long‑term hold.

Why Traders Are Watching CAPR’s Deramiocel Pivot

Capricor Therapeutics (CAPR) is suddenly back on every biotech day‑trader’s screen. The move started when the FDA agreed to review an amendment to the biologics license application (BLA) for deramiocel, CAPR’s cell therapy for Duchenne muscular dystrophy. Earlier, a 9–3 negative advisory committee vote on the original cardiomyopathy indication looked like a death blow. Instead, Capricor is pivoting.

Now CAPR is refocusing deramiocel on upper‑limb skeletal muscle function, where it has cleaner data. The HOPE‑3 Phase 3 trial hit its primary upper‑limb endpoint, and those results were strong enough to land in The Lancet. Capricor plans to pack the amended BLA with 24‑month open‑label extension data and refined analyses keyed directly to that endpoint. The FDA has signaled it is open to reviewing this new package and extending the PDUFA date, effectively keeping the door open, though on a narrower path.

Traders are treating that signal as a green light. CAPR shares surged roughly 80–100% in premarket and regular trading once the FDA’s stance and the BLA amendment plan hit the tape. At the same time, Cantor Fitzgerald stepped in with a bold call, upgrading Capricor Therapeutics to Overweight from Neutral and hiking its price target to $28 from $3.50. That new target sits above the prior Street average of $26.12, making Cantor’s view one of the most bullish on CAPR.

The market is now pricing Capricor Therapeutics as a single‑asset, high‑stakes story: if deramiocel clears this new regulatory hurdle, CAPR has major upside; if not, the air pocket below is real.

Conclusion

For short‑term traders, CAPR is the kind of setup that defines biotech momentum. The company has no current product revenue, a widening loss, and return metrics deep in the red, yet roughly $238M in cash and short‑term investments provide enough runway for at least 12 months. Capricor Therapeutics is trimming non‑deramiocel programs, moderating commercial spend, and even dealing with an NS Pharma distribution dispute headed to arbitration. All of that just reinforces one thing: deramiocel is the whole game.

With the FDA willing to review an amended BLA and extend the PDUFA date, CAPR now trades on each regulatory headline and every hint about upper‑limb data. The strong HOPE‑3 Phase 3 result and publication in The Lancet give Capricor Therapeutics scientific backing, but the prior negative advisory vote shows the risk is still binary. Add Cantor Fitzgerald’s aggressive $28 target and Overweight rating, and CAPR becomes a pure sentiment and catalyst chart.

Traders who follow Tim Sykes’ style focus on exactly this kind of name: liquid, news‑driven, and volatile. As Sykes likes to say, “The market rewards preparation, not prediction.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” With Capricor Therapeutics, that means studying the chart, knowing the deramiocel timeline, and being ready to cut losses fast if the FDA story turns. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!